Track Neoleukin Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Neoleukin Therapeutics, Inc. NLTX · Stock Open Neoleukin Therapeutics, Inc. in new tab

3.49 USD
Loading chart...

DCF valuation

Model fair value for Neoleukin Therapeutics, Inc. (NLTX)
Result
Sign in to run the valuation for NLTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Neoleukin Therapeutics, Inc. Logo Neoleukin Therapeutics, Inc. Analysis (NLTX)

United States Health Care Official Website Stock

Is Neoleukin Therapeutics, Inc. a good investment? Neoleukin Therapeutics, Inc. (NLTX) is currently trading at 3.49 USD.

Investor FAQ

Does Neoleukin Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Neoleukin Therapeutics, Inc.?

Neoleukin Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Exchange Ticker
NMS (United States) NLTX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 25, 2023 1:5
Dec. 19, 2023 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion